Patents Assigned to Temple University
-
Patent number: 6362171Abstract: Antiviral compounds and the water-soluble salts thereof have formula (I), wherein n is from 1 to 8; R1 is selected from the group consisting of (a), wherein m is zero, 1, 2 or 3; and (b), wherein q is from 1 to 20; R2 is independently selected from the group consisting of oxygen and sulfur; R3 is independently selected from the group consisting of hydrogen and hydroxyl; and R4 is selected from the group consisting of hydrogen, hydroxyl and (b); R5 is selected from the group consisting of hydroxyl and (b); R6 is selected from the group consisting of (c), (d) et (e), wherein x is from 1 to 20; provided that one of R1, R4 and R5 is (b) wherein R6 is defined as above; or water soluble salt thereof.Type: GrantFiled: December 9, 1999Date of Patent: March 26, 2002Assignee: Temple University-of the Commonwealth System of Higher EducationInventors: Robert J. Suhadolnik, Wolfgang Pfleiderer
-
Patent number: 6359013Abstract: Styryl sulfone compounds of the invention selectively inhibit proliferation of tumor cells, and induce apoptosis of such tumor cells, while sparing normal cells.Type: GrantFiled: March 24, 2000Date of Patent: March 19, 2002Assignee: Temple University-of the Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Patent number: 6347941Abstract: A dental bur for use in repair of a carious lesion has a working surface including cutting elements which deflect or abrade upon encountering material having a hardness at or above a preselected hardness, wherein said preselected hardness is below the hardness of normal dentin and is generally below a hardness corresponding to the lower limit of hardness of pre-carious dentin to be retained in painless procedures.Type: GrantFiled: February 23, 2001Date of Patent: February 19, 2002Assignee: Temple University of the Commonwealth System of Higher EducationInventor: Daniel W. Boston
-
Patent number: 6337091Abstract: The present invention provides a new simple polymeric matrix tablet that delivers highly soluble drugs over long periods of time and is easy to manufacture. More specifically, the drug is first granulated with or encapsulated in a swellable polymer, such as a gum, to form a granule. This granule is disposed in a matrix of a more swellable, erodible polymer, such as HPMC or Polyethyleneoxide, and optionally includes pectin. The more swellable erodible polymer has a diffusion rate coefficient which is greater than the diffusion rate coefficient of the relatively less swellable polymer. It is this difference in diffusion rate coefficients between the first and second polymers which controls the rate of drug release and allows the system to approach zero order drug delivery over the drug release period. Other advantages which the present invention holds over existing systems including ease of manufacturing and reproducibility of release profiles under well defined hydrodynamic conditions.Type: GrantFiled: October 27, 1997Date of Patent: January 8, 2002Assignee: Temple University - of the Commonwealth System of Higher EducationInventors: Hyunjo Kim, Reza Fassihi
-
Patent number: 6284726Abstract: Peptide analogs of the high molecular weight kininogen domain 5 are potent inhibitors of angiogenesis. The peptides have the formula X1-(HGLGHGHEQQHGKGH)-X2 (I) wherein X1 is from zero to 25 amino acids; X2 is from zero to 60 amino acids. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.Type: GrantFiled: July 7, 2000Date of Patent: September 4, 2001Assignees: Temple University - Of The Commonwealth System of Higher Education, Du Pont Pharmaceuticals CompanyInventors: Robert W. Colman, Shaker A. Mousa
-
Patent number: 6281201Abstract: Antiviral compounds have the formula wherein m is zero, 1, 2 or 3; n is from 1 to 8, preferably 1, 2 or 3; most preferably 1 or 2; R is independently selected from the group consisting of provided that all R may not be R1 is independently selected from the group consisting of hydroxyl and hydrogen; R2 is independently selected from the group consisting of oxygen and sulfur; or water soluble salts thereof.Type: GrantFiled: December 8, 1999Date of Patent: August 28, 2001Assignee: Temple University- of the Commonwealth System of Higher EducationInventors: Robert J. Suhadolnik, Wolfgang Pfleiderer
-
Patent number: 6257889Abstract: A dental bur for use in examining anomalies and in restoration of decayed areas of teeth with a bur head having a generally elongate conical shaped body with a base and an opposed vertex. Cutting members are located about the outer surface of the body between the base and vertex and extend along the outer surface of the bur head which has a length of at least 1.5 millimeters.Type: GrantFiled: March 25, 1999Date of Patent: July 10, 2001Assignee: Temple University - of the Commonwealth System of Higher EducationInventor: Daniel W. Boston
-
Patent number: 6232019Abstract: Gel electrolytes for electrochromic and electrochemical devices wherein in one embodiment polymeric gelling agents/atactic or syndiotactic, and isotactic PMMA, and a lithium salt in a suitable solvent are dissolved at a temperature above the gelation point and cooled to form a gel electrolyte. In another embodiment a preelectrolyte film is formed by casting a solution of a mixture of stereocomplexed PMMA with a plasticizer (a complexing low molecular weight polar solvent) in a non-complexing volatile solvent (e.i., CClH3), followed by the activation of the film in a liquid electrolyte which includes a lithium salt and low molecular weight complexing solvents to form the completed gel electrolyte.Type: GrantFiled: November 2, 1998Date of Patent: May 15, 2001Assignees: Lithium Technology Corporation, Temple University-of the Commonwealth System of Higher EducationInventors: Stephanie L. Wunder, Hong Peng Wang, Yury K. Yarovoy
-
Patent number: 6214554Abstract: Chronic fatigue syndrome is diagnosed through detection of an about 30 kDa RNase L molecule under native conditions in cellular extracts of RNase L-containing cells such as peripheral blood mononuclear cells. Proteins are fractionated according to molecular weight under nondenaturing conditions. The fractionated proteins are assayed for the presence of the about 30 kDa protein having 2-5A-dependent RNase L enzyme activity. The severity of the affliction may be determined by testing for the presence of RNase L molecules having approximate molecular weights of 30 and 80 kDa. The presence of the about 30 kDa RNase L, and the absence of the about 80 kDa RNase L molecule, correlates with severe chronic fatigue syndrome. The presence of both RNase L molecules indicates a less severe chronic fatigue syndrome affliction. Under denaturing conditions, and in the presence of protease inhibitors, chronic fatigue syndrome may be diagnosed through the detection of an about 37 kDa 2-5A binding protein.Type: GrantFiled: April 21, 1999Date of Patent: April 10, 2001Assignee: Temple University of the Commonwealth System of Higher EducationInventor: Robert J. Suhadolnik
-
Patent number: 6207366Abstract: Chronic fatigue syndrome is diagnosed through quantification of low and high molecular weight forms of RNase L in cellular extracts of RNase L-containing cells such as peripheral blood mononuclear cells. A ratio of low to high molecular weight RNase L of more than 0.15 is characteristic of chronic fatigue syndrome.Type: GrantFiled: April 13, 2000Date of Patent: March 27, 2001Assignee: Temple University- Of the Commonwealth System of Higher EducationInventor: Robert J. Suhadolnik
-
Patent number: 6201154Abstract: (Z)-styryl benzylsulfones of formula I are useful as anticancer agents: wherein R1 is selected from the group consisting of hydrogen, chloro and nitro; R2 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, chloro, bromo, and fluoro; and R3 and R4 are independently selected from the group consisting of hydrogen, lower alkyl, nitro, chloro, bromo, and fluoro; provided that at least one of R1 or R2 is hydrogen. The corresponding (Z)-styryl benzylsulfides are useful as intermediates in the preparation of the biologically active (Z)-styryl benzyl sulfones.Type: GrantFiled: March 31, 1999Date of Patent: March 13, 2001Assignee: Temple University-of the Commonwealth of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Patent number: 6110500Abstract: A tablet for the controlled release of an active pharmaceutical ingredient. The tablet comprises a core having a donut-like configuration with a cylindrical hole extending through the center of the core. The core of the body comprises at least one active pharmaceutical agent and at least one hydrophilic, water-soluble, polymeric carrier. The core is coated with a hydrophobic, water-insoluble material covering all of the core except that which is defined by the cylindrical hole. Also included is a method of preparing a tablet for the controlled release of an active ingredient. The method comprises the steps of blending an active pharmaceutical ingredient, a water-soluble hydrophilic, polymeric carrier, and optionally an excipient, to form a mix; compressing the mix; punching a tablet from the mix; coating the tablet in a water insoluble, hydrophobic coating, then drilling a hole through the coated tablet.Type: GrantFiled: March 25, 1998Date of Patent: August 29, 2000Assignee: Temple UniversityInventor: Cherng-ju Kim
-
Patent number: 6105572Abstract: A liquid ventilator having a dual loop, single pump configuration is disclosed. The liquid ventilator preferably utilizes two three-way valves for routing liquid from a reservoir in a regeneration apparatus and to a patient's pulmonary system, and back to the reservoir again. A controller controls the configuration of the three-way valves and the pump speed of the motor to allow user control over the parameters of inspiration and expiration.Type: GrantFiled: November 7, 1997Date of Patent: August 22, 2000Assignees: Alliance Pharmaceutical Corp., Temple University of the Commonwealth System of Higher EducationInventors: Thomas H. Shaffer, Marla R. Wolfson, James L. Heckman, John Hoffman
-
Patent number: 6106291Abstract: A dental bur has a working surface including cutting elements which deflect or abrade upon encountering material at or above the preselected hardness corresponding to the lower limit of hardness of non-carious dentin. The dental bur is constructed of metal, ceramic, or plastic.Type: GrantFiled: December 15, 1998Date of Patent: August 22, 2000Assignee: Temple University of the Commonwealth System of Higher EducationInventor: Daniel W. Boston
-
Patent number: 6090580Abstract: An isolated transcribed nucleotide sequence, termed interferon Responsive Transcript -1 (IRT-1), encodes a deduced 132 amino acid basically-charged protein. The invention is directed to IRT-1 nucleic acid, its structural and functional homologs, including portions of the nucleotide, and complements of the nucleotide sequence. Also provided are isolated amino acid sequences encoded by the IRT-1 nucleotide sequences, structural and functional homologs of the isolated amino acid sequences, including portions of the amino acid sequences and antibodies to the amino acid sequences. The IRT-1 nucleic acid sequences may be used to detect and produce other sequences, to regulate or oppose production of vascular smooth muscle cells, and to prevent or treat proliferative arterial disease and/or vascular restenosis.Type: GrantFiled: January 2, 1998Date of Patent: July 18, 2000Assignee: Temple University of the Commonwealth System of Higher EducationInventor: Michael V. Autieri
-
Patent number: 6090411Abstract: A swellable hydrophillic matrix tablet that delivers drugs in a controlled manner over a long period of time and is easy to manufacture. More specifically, the drug is disposed in a matrix composed of HPMC or polyethylene oxide, in the presence of a salt, which may be a combination of salts. Suitable salts include sodium bicarbonate, sodium chloride, potassium bicarbonate, calcium chloride, sodium bisulfate, sodium sulfite, and magnesium sulfate. Outward diffusion of the drug is controlled by an inwardly progressing hardening reaction between the salt and the dissolution medium, possibly also involving the drug itself.Type: GrantFiled: March 9, 1998Date of Patent: July 18, 2000Assignee: Temple UniversityInventors: Viness Pillay, Reza Fassihi
-
Patent number: 5989849Abstract: Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-kit gene. These "antisense" oligonucleotides are hybridizable to the c-kit mRNA transcript. Such oligonucleotides are useful in selectively inhibiting proliferation of erythroid cells, particularly in disorders characterized by an elevated hematocrit due to over-production of erythrocytes. The antisense oligomers also have activity agent hematologic neoplastic cells and are therefore suitable as bone marrow purging agents.Type: GrantFiled: June 5, 1995Date of Patent: November 23, 1999Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Alan M. Gewirtz, Bruno Calabretta
-
Patent number: 5985565Abstract: Chronic fatigue syndrome is diagnosed through detection of an about 30 kDa RNase L molecule under native conditions in cellular extracts of RNase L-containing cells such as peripheral blood mononuclear cells. Proteins are fractionated according to molecular weight under nondenaturing conditions. The fractionated proteins are assayed for the presence of the about 30 kDa protein having 2-5A-dependent RNase L enzyme activity. The severity of the affliction may be determined by testing for the presence of RNase L molecules having approximate molecular weights of 30 and 80 kDa. The presence of the about 30 kDa RNase L, and the absence of the about 80 kDa RNase L molecule, correlates with severe chronic fatigue syndrome. The presence of both RNase L molecules indicates a less severe chronic fatigue syndrome affliction. Under denaturing conditions, and in the presence of protease inhibitors, chronic fatigue syndrome may be diagnosed through the detection of an about 37 kDa 2-5A binding protein.Type: GrantFiled: July 16, 1997Date of Patent: November 16, 1999Assignee: Temple University-of the Commonwealth System of Higher EducationInventor: Robert J. Suhadolnik
-
Patent number: 5945125Abstract: A controlled release tablet including a pharmaceutical agent and an excipient. The excipient includes at least about 60% of a water swellable polymer and a lubricant. The water swellable polymer is chosen such that the swelling rate of the polymer is equal to the dissolution rate of the swollen polymer. The excipient may also include such other ingredients as diluents, fillers, binders, solubilizers, emulsifiers, and other pharmacologically inactive compounds. The polymer is chosen with the pharmaceutical agent in mind such that the tablet will be fully dissolved at the same time that the last of the pharmaceutical agent is released.Type: GrantFiled: June 21, 1996Date of Patent: August 31, 1999Assignee: Temple UniversityInventor: Cherng-ju Kim
-
Patent number: RE36840Abstract: A method and system for displaying a function in two dimensions where the function is made up of numerous independent variables and at least one dependent variable. A new independent variable value can be defined having values which correspond to the multiple dependent variables. The variable values are read into a computer and the independent variables are then ranked by the user from fastest- to slowest-running variable. Each dependent variable corresponding to the new independent variable is plotted along the Y-axis. The independent variable values are plotted along the X-axis in a hierarchical manner. The hierarchical manner involves a nesting of fastest-running variables within slower-running variables. Rectangles are then drawn to correspond to each variable value. Each rectangle horizontally encloses the faster-running variables associated with it.Type: GrantFiled: July 3, 1995Date of Patent: August 29, 2000Assignee: Temple UniversityInventors: Ted W. Mihalisin, John Timlin, Edward T. Gawlinski, John W. Schwegler